Kidney shield? experimental drug aims to prevent Post-Surgery kidney damage

NCT ID NCT06602453

Terminated Prevention Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 23 times

Summary

This phase 2 trial tested a drug called GDC-8264 to see if it could prevent acute kidney injury and major kidney problems in people having heart surgery. The study enrolled 67 participants at moderate to high risk. However, the trial was terminated early, so the full results are not available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

APHP - Hopital de la Pitie Salpetriere

Paris, 75013, France
Auckland City Hospital

Auckland, 1023, New Zealand
Baystate Cardiac Surgery

Springfield, Massachusetts, 01107, United States
C.H. Regional Reina Sofia - PPDS

Córdoba, 14004, Spain
CHI Health Nebraska Heart

Lincoln, Nebraska, 68526-9437, United States
CHU Angers

Angers, 49933, France
CHU de Reims

Reims, 51092, France
Duke University Medical Center

Durham, North Carolina, 27705, United States
Fakultni nemocnice v Motole

Prague, 150 06, Czechia
Fiona Stanley Hospital

Murdoch, Western Australia, 6150, Australia
Gold Coast University Hospital

Southport, Queensland, 4215, Australia
Herzzentrum Dresden GmbH Universitatsklinikum

Dresden, 01307, Germany
Hopital de la Citadelle

Liège, 4000, Belgium
Hospital Universitario Germans Trias i Pujol

Badalona, Barcelona, 08916, Spain
Hospital Universitario de Bellvitge

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Hospital Universitario de La Princesa

Madrid, 28006, Spain
James A Haley Veteran Affairs Medical Center - NAVREF - PPDS

Tampa, Florida, 33612-4745, United States
John Hopkins Hospital

Lutherville, Maryland, 21093, United States
Mayo Clinic - PPDS

Rochester, Minnesota, 55905-0001, United States
Radboud Universitair Medisch Centrum

Nijmegen, 6525 GA, Netherlands
Richmond VA Medical Center NAVREF PPDS

Richmond, Virginia, 99999, United States
Royal Infirmary of Edinburgh

Edinburgh, EH16 4SA, United Kingdom
Saint John Regional Hospital

Saint John, New Brunswick, E2L 4L2, Canada
Samsung Medical Center - PPDS

Seoul, 06351, South Korea
Severance Hospital Yonsei University Health System - PPDS

Seoul, 03722, South Korea
Southampton General Hospital

Southampton, SO16 6YD, United Kingdom
Townsville Hospital

Townsville, Queensland, 4810, Australia
UZ Leuven

Leuven, 3000, Belgium
University of Stanford Medical Center

Stanford, California, 94305-2200, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390-7202, United States
Universitätsklinikum Essen

Essen, 45147, Germany
Vseobecna fakultni nemocnice v Praze

Prague, 12808, Czechia
Waikato Hospital

Hamilton, 3248, New Zealand
ZOL Genk campus Sint Jan

Genk, 3600, Belgium

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GDC-8264 (a drug given as a pill or injection)

What this could lead to

If it works, this could point toward a way to prevent kidney damage after heart surgery, reducing the need for dialysis and long-term kidney problems.

What could go wrong

The trial was terminated early, so results are limited. It was a small phase 2 study, and the drug may not prove effective or safe in larger groups.

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY